Xilio Therapeutics, Inc. (XLO) Stock Price, Financials & Summary

Price chart

Oct 1Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30

Key dataOct 30, 2026

Open$8.14

From 52W high−32.52%

Volume8009.00

Market cap$52.84M

P/E (TTM)—

P/S (TTM)0.8x

Div yield—

Key dataOct 30, 2026

Open

$8.14

From 52W high

−32.52%

Volume

8009.00

Market cap

$52.84M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

3.8x

P/E (TTM)

—

RSI (14)

42.5

MomentumView details →

1D Return

+3.35%

YTD Return

−10.16%

SummaryUpdated Jun 1, 2026

Xilio Therapeutics, Inc. (NASDAQ:XLO) is a clinical-stage biotechnology company founded in 2016 and headquartered in Waltham, Massachusetts. The company went public in October 2021 and focuses on developing innovative immunotherapies designed to enhance the immune system's ability to fight cancer. Xilio specializes in creating tumor-selective treatments that aim to overcome the limitations of traditional cancer immunotherapies by concentrating therapeutic activity specifically within the tumor microenvironment while minimizing systemic side effects.

Ask drillr about Xilio Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

3.8x

EV/Sales

−1.2x

P/S (TTM)

0.8x

P/B (TTM)

0.7x

ProfitabilityView details →

Gross Margin

99.46%

Net Margin

−34.06%

EBITDA Margin

−31.97%

ROE (TTM)

−30.21%

ROA (TTM)

−14.15%

Asset Turnover

0.40x

GrowthView details →

Revenue YoY

+327.25%

EPS YoY

+88.30%

FCF YoY

—

Revenue CAGR 3Y

+589.88%

EPS CAGR 3Y

+72.54%

EBITDA YoY

+63.35%

MomentumView details →

1D Return

+3.35%

YTD Return

−10.16%

1Y Return

−27.80%

RSI (14)

42.5

vs 50D SMA

−8.54%

vs 200D SMA

−5.24%

Capital & dividendView details →

Debt/Equity

0.09x

Current Ratio

4.25x

Quick Ratio

4.25x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.33

EPS Surprise

44.07%

Beats (12Q)

7/12

Next Q EPS Est

−$0.98

Avg Surprise (4Q)

26.40%

Rev Surprise

46.95%

Financials snapshotView financials →

Revenue (TTM)

64.09M

Net Income (TTM)

−21.83M

Op. CF (TTM)

−60.60M

Next earningsNov 12, 2026 →

Latest newsMore news →

Xilio Therapeutics, Inc. announced that the first patient had been dosed in a Phase 1/2 clinical trial of XTX501 for metastatic non-small cell lung cancer.4d ago

Xilio Therapeutics, Inc. hired Yariv Houvras as chief medical officer.14d ago

Similar companies

Heron Therapeutics, Inc.HRTX Pliant Therapeutics, Inc.PLRX Coeptis Therapeutics, Inc.COEP MiNK Therapeutics, Inc.INKT MindWalk Holdings Corp.HYFT Kezar Life Sciences, Inc.KZR Find similar companies →

Latest newsMore news →

Xilio Therapeutics, Inc. announced that the first patient had been dosed in a Phase 1/2 clinical trial of XTX501 for metastatic non-small cell lung cancer.4d ago Xilio Therapeutics, Inc. hired Yariv Houvras as chief medical officer.14d ago